<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164856">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926197</url>
  </required_header>
  <id_info>
    <org_study_id>PANC0015</org_study_id>
    <secondary_id>27492</secondary_id>
    <nct_id>NCT01926197</nct_id>
  </id_info>
  <brief_title>Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial

      Primary Objective:

      To determine progression free survival for mFFX +/- SBRT.

      Secondary Objectives:

        -  To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.

        -  To determine the overall survival in pancreatic cancer patients treated with
           chemotherapy +/- SBRT.

        -  To determine local progression-free survival in pancreatic cancer patients after
           chemotherapy +/- SBRT.

        -  To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,
           enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months
           of treatment.

        -  To evaluate the utility of FDG-PET for treatment planning and estimation of progression
           free survival.

        -  To identify new biomarkers in pancreatic cancer.

        -  To evaluate the quality of life of patients before and after either chemotherapy or
           chemotherapy and SBRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial

      Primary Objective:

      To determine progression free survival for mFFX +/- SBRT.

      Secondary Objectives:

        -  To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.

        -  To determine the overall survival in pancreatic cancer patients treated with
           chemotherapy +/- SBRT.

        -  To determine local progression-free survival in pancreatic cancer patients after
           chemotherapy +/- SBRT.

        -  To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,
           enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months
           of treatment.

        -  To evaluate the utility of FDG-PET for treatment planning and estimation of progression
           free survival.

        -  To identify new biomarkers in pancreatic cancer.

        -  To evaluate the quality of life of patients before and after either chemotherapy or
           chemotherapy and SBRT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Parallel Assignment, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>difference in progression-free survival between mFOLFIRINOX alone vs. mFOLFIRINOX and SBRT</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFIRINOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFFX+SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFIRINOX + SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU</intervention_name>
    <arm_group_label>mFFX</arm_group_label>
    <arm_group_label>mFFX+SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the pancreas.

          -  Induction mFolfirinox no more than 2 cycles.

          -  Stable or better disease on re-staging scans following induction mFolfirinox.
             Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or
             gastrointestinal oncology Tumor Board.

          -  SBRT treatment plan must satisfy all normal tissue constraints.  Minor protocol
             deviations will be considered on an individual basis and must be approved by
             Coordinating Center Principal Investigator or Co-Investigator.

          -  Age &gt;18 years.

          -  Karnofsky &gt;70% (see Appendix II).

          -  Acceptable organ and marrow function (as defined in Section 3.1).

          -  Women who are not post-menopausal (defined in Appendix III) should have a negative
             urine or serum pregnancy test.

          -  Women and men of childbearing potential must agree to use adequate contraception for
             the duration of study participation.

        Exclusion Criteria:

          -  No metastatic disease.

          -  No prior upper abdominal or liver radiation therapy.

          -  Chemotherapy other than 2 cycles mFolfirinox.

          -  No uncontrolled illness or active infection requiring systemic antibiotic treatment.

        No concurrent malignancies other than non-melanoma skin cancer, non-invasive bladder
        cancer and carcinoma in situ of the cervix; and no other cancers within 5 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Ann Columbo</last_name>
      <phone>650-736-0792</phone>
      <email>lcolumbo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Koong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
